Schorno Dean L 4
4 · RIGEL PHARMACEUTICALS INC · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Rigel (RIGL) CFO Dean Schorno Receives Performance-Based Option Award
What Happened
Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), was credited with a performance-based stock option covering 7,394 shares on June 17, 2026. The Form 4 reports an acquisition of 7,394 derivative securities at $0.00 (code A). The option's exercise price is $22.49 per share (set at grant), and the vesting occurred because a performance metric was satisfied on June 17, 2026.
Key Details
- Transaction date: June 17, 2026 — reported on Form 4 filed June 22, 2026.
- Reported transaction: Award/vesting of a stock option covering 7,394 shares (derivative securities), acquisition price shown as $0.00.
- Exercise price: $22.49 per share (set at grant on January 29, 2025).
- Vesting: The option was fully vested on June 17, 2026 when the performance condition was met (per footnotes).
- Shares owned after transaction: Not specified in the provided filing.
- Filing timeliness: The Form 4 was filed five days after the transaction date (appears late versus the usual two-business-day reporting requirement).
- Footnotes: F1 explains the option was granted 1/29/2025 with performance-based vesting; F2 confirms the option fully vested on 6/17/2026.
Context
- This report reflects a vesting/award of a stock option (derivative), not a cash purchase or a sale. There is no indication in the filing that the option was exercised or that any shares were sold immediately.
- For retail investors, vesting of performance-based awards signals the company recorded achievement of whatever internal metric triggered the grant; it is not a direct buy/sell signal by the insider.
Insider Transaction Report
Form 4
Schorno Dean L
EVP & Chief Financial Officer
Transactions
- Award
Employee Stock Option (right to buy)
[F1][F2]2026-06-17+7,394→ 7,394 totalExercise: $22.49Exp: 2035-01-29→ Common Stock (7,394 underlying)
Footnotes (2)
- [F1]The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- [F2]The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Signature
/s/ Raymond Furey (Attorney-in-Fact)|2026-06-22